Endothelial Injury in COVID-19 and Acute Infections
2021; Lippincott Williams & Wilkins; Volume: 41; Issue: 5 Linguagem: Inglês
10.1161/atvbaha.121.316101
ISSN1524-4636
AutoresJerrold H. Levy, Toshiaki Iba, Elizabeth E. Gardiner,
Tópico(s)Long-Term Effects of COVID-19
ResumoHomeArteriosclerosis, Thrombosis, and Vascular BiologyVol. 41, No. 5Endothelial Injury in COVID-19 and Acute Infections Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBEndothelial Injury in COVID-19 and Acute InfectionsPutting the Pieces of the Puzzle Together Jerrold H. Levy, Toshiaki Iba and Elizabeth E. Gardiner Jerrold H. LevyJerrold H. Levy Correspondence to: Jerrold H. Levy, MD, FAHA, Duke University Medical Center, 2301 Erwin Rd, 5691H HAFS Box 3094, Durham, NC 27710. Email E-mail Address: [email protected] https://orcid.org/0000-0003-3766-4962 Departments of Anesthesiology (J.H.L.), Duke University School of Medicine, Durham, NC. Critical Care (J.H.L.), Duke University School of Medicine, Durham, NC. Surgery (J.H.L.), Duke University School of Medicine, Durham, NC. , Toshiaki IbaToshiaki Iba https://orcid.org/0000-0002-0255-4088 Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan (T.I.). and Elizabeth E. GardinerElizabeth E. Gardiner https://orcid.org/0000-0001-9453-9688 ACRF Department of Cancer Biology and Therapeutics, Australian National University, Canberra (E.E.G.). Originally published1 Apr 2021https://doi.org/10.1161/ATVBAHA.121.316101Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41:1774–1776This article is a commentary on the followingVascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: April 1, 2021: Ahead of Print Beyond respiratory and renal failure in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), also known as coronavirus disease 2019 (COVID-19), COVID-19–associated coagulopathy is a major challenge with a high incidence of thromboembolic complications.1 Endothelial vascular injury and thromboinflammation associated with SARS-CoV2 viral infections are emerging as likely culprits mediating the pathology and some of the clinical manifestations of COVID-19.2,3 In this issue of ATVB, Dupont et al4 from the Lille COVID Research Network Group quantify vascular endothelial damage as part of the pathogenesis of organ injury in severe COVID-19. They investigated the contribution of endotheliopathy to microvascular thrombosis and multiorgan failure by examining biomarkers of endothelial damage from 82 COVID-19 patients on admission to an intensive care unit. Interestingly, the investigators also performed histological examination of thrombi retrieved from the extracorporeal membrane oxygenation circuitry supporting 8 COVID-19 and 3 control patients following weaning from extracorporeal membrane oxygenation support. Understanding how different biomarkers of vascular injury and thromboinflammation behave across the course of the disease could help in identifying severe disease earlier, aid in clinical decisions around therapeutics and management, and subsequently improve prognosis.See accompanying article on page 1760The endothelium has major functions in the vasculature to control vascular permeability and tone, which are largely controlled by NO release from the endothelium.5 Maintenance of platelet passivity and control of coagulation are also achieved, in part, by expression of endothelial proteins and secretion of factors aimed at controlling thrombin generation and platelet activation (Figure). During COVID-19 infection, critically ill patients can have disrupted coagulation function, predisposing them to consumptive coagulopathies, with both venous and thromboembolic complications, often with unique characteristics.6,7 Elevated fibrinogen, D-dimer, and other biomarkers released from damaged endothelium have all been associated with increased disease severity. Further, pulmonary embolism, deep vein thrombosis, ischemic stroke, myocardial infarction, and systemic arterial embolism have all been noted, implying a dramatic dysregulation of hemostasis, despite hospitalized patients receiving standard thromboprophylaxis.8 In the current study,4 the investigators measured an extensive panel of biomarkers that included endothelial damage markers in plasma such as VWF (von Willebrand factor), PAI-1 (plasminogen activator inhibitor-1), syndecan-1, and soluble thrombomodulin and could demonstrate an association of elevated levels at intensive care unit admission, with respiratory and multiorgan failure, liver injury, and death in COVID-19 patients. Plasma-based proinflammatory cytokines including IL (interleukin)-6, TNFα (tumor necrosis factor alpha), IL-2R (IL-2 receptor), and components of neutrophil extracellular traps including cell-free DNA, nucleosomes, MPO (myeloperoxidase)-DNA, as well as TFPI (tissue factor pathway inhibitor), C5a (complement 5a), and membrane attack component (MAC; C5b-9; Figure) were also elevated. As the field of biomarker data from critically ill COVID-19 patients accumulates, what is important is to ascertain what can be done with the bank of information regarding thromboinflammatory responses in patients vis-à-vis management strategies. Nonetheless, this study suggests that thromboinflammation contributes significantly to the primary pathophysiology of COVID-19.Download figureDownload PowerPointFigure. Damage to the endothelium could underpin the thrombosis and inflammation induced by coronavirus disease 2019 (COVID-19) viremia. The healthy endothelium provides a passive, nonadhesive protective barrier with broad anticoagulant properties. Upon damage, the surface becomes adhesive for both platelets and leukocytes and is highly procoagulant. As part of the thromboinflammatory process to limit the spread of an invading pathogen, the onset of NETosis ensues. Signaling the endothelium damage, markers such as VWF (von Willebrand factor), PAI-1 (plasminogen activator inhibitor 1), syndecan-1, and soluble thrombomodulin increase in plasma. Further, proinflammatory cytokines such as IL (interleukin)-6, TNFα (tumor necrosis factor alpha), IL-2R (IL-2 receptor), and neutrophil extracellular traps (NETs) components including cell-free DNA, nucleosomes, and MPO (myeloperoxidase)-DNA were also elevated. TFPI (tissue factor pathway inhibitor), C5a (complement 5a), and membrane attack component (MAC; C5b-9) are also potential biomarkers in COVID-19.As the pathophysiology of COVID-19–associated coagulopathy is complex and could differ in important ways from the common mechanisms of thrombosis reported in critically ill patients,9 the physical characteristics of blood clots may provide some important clues. In other studies,10 data gathered from thrombi isolated postmortem from COVID-19 patients may be difficult to interpret due to confounding factors indolent to samples from people treated for extended periods in intensive care unit facilities. Dupont et al performed histological examination of thrombi isolated from the extracorporeal membrane oxygenation tubing of COVID-19 or non–COVID-19 patients following successful separation from extracorporeal membrane oxygenation life support. Although thrombi from mechanical support devices do not necessarily reflect the properties of thrombi formed within a patient's vasculature, these thrombi showed a considerable accumulation of nucleated cells, primarily neutrophils, and citrullinated histones, indicative of active NETosis. Consistent with this, a recent report demonstrated that neutrophil activation precedes the onset of critical COVID-19 illness and predicts mortality.11 Following acute infections, multiple host surveillance and defense pathways have evolved to eradicate or restrain pathogens, and in this regard, the host responses to COVID-19 infection are not likely to differ from responses to other viremias. The acute inflammatory responses have long been known to cause vascular endothelial injury and orchestrate complex cellular and humoral thromboinflammatory and hypercoagulable responses, also called immunothrombosis.12 In this scenario, neutrophils and VWF may act as a scaffold for thrombus formation and the immunothrombotic injury of COVID-19. Based on the current report, a multitude of bioactive cellular components, including procoagulants released from the damaged endothelium and during cell death, are major contributors to the observed multiorgan injury.A major hallmark of COVID-19 is the acute lung injury from an initial viral load delivered from the respiratory tract to the lung, resulting in alveolar and microvascular injury.13 Reports of pulmonary infection-induced microvascular and macrovascular thrombosis in patients with adult respiratory distress syndrome have existed for >30 years.14 However, in many patients with COVID-19, this localized thromboinflammatory response in the pulmonary microcirculation can progress to a systemic response, as the authors have shown in their report, a finding consistent with the exuberant inflammatory response to viral infection observed in SARS-CoV-2. The extent of systemic transition is likely to explain the variability of multiorgan dysfunction observed as COVID-19 progresses, and is where a panel of biomarkers ideally in combination with other vascular markers,15 may have utility as sentinels of that transition.Based on the extensive investigation of standard and novel biomarkers,4,11,16,17 can we stratify patients and personalize potential therapeutic approaches to mollify the complex endothelial injury due to thromboinflammation? The extensive endothelial injury associated with SARS-CoV-2, as well as in other acute infectious processes including bacterial induced septic shock and disseminated intravascular coagulopathy, continues to be a major driver of thromboinflammatory injury.3 A major problem with treating the acute inflammatory injury of SARS-CoV-2 is that treatment after the acute inflammatory insult limits the potential benefits of these therapeutic interventions. Of course, it is essential to keep in mind that association does not necessarily mean causality, and prior efforts at antagonizing specific mediators both in COVID-19 and other major infectious processes like septic shock with disseminated intravascular coagulopathy have not been shown to consistently reduce mortality.18 Nonetheless, continuing research on endothelial injury in COVID-19 to enhance understanding of the pathophysiological features will help us to piece together the puzzle of this thromboinflammatory state and refine existing and develop new therapeutic approaches to treat the acute COVID-19 disease state.AcknowledgmentsJ.H. Levy, T. Iba, and E.E. Gardiner contributed to the writing of the manuscript.Sources of FundingThis study was funded by the National Health and Medical Research Council of Australia and local institutional sources.Disclosures J.H. Levy serves on research, data safety, or advisory committees for Instrumentation Labs, Merck, and Octapharma. T. Iba receives research grants from Japan Blood Products Organization and JIMRO. The other author reports no conflicts.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Sources of Funding and Disclosures, see page 1776.Correspondence to: Jerrold H. Levy, MD, FAHA, Duke University Medical Center, 2301 Erwin Rd, 5691H HAFS Box 3094, Durham, NC 27710. Email jerrold.levy@duke.eduReferences1. Jiménez D, García-Sanchez A, Rali P, Muriel A, Bikdeli B, Ruiz-Artacho P, Le Mao R, Rodríguez C, Hunt BJ, Monreal M. Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis.Chest. 2021; 159:1182–1196.CrossrefMedlineGoogle Scholar2. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches.Signal Transduct Target Ther. 2020; 5:293. doi: 10.1038/s41392-020-00454-7CrossrefMedlineGoogle Scholar3. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in covid-19.N Engl J Med. 2020; 383:120–128. doi: 10.1056/NEJMoa2015432CrossrefMedlineGoogle Scholar4. Dupont A, Rauch A, Staessens S, Moussa M, Rosa M, Corseaux D, Jeanpierre E, Goutay J, Caplan M, Varlet P, et al. Vascular endothelial damage in the pathogenesis of organ injury in severe COVID-19.Arterioscler Thromb Vasc Biol. 2021; 41:1760–1773. doi: 10.1161/ATVBAHA.120.315595LinkGoogle Scholar5. Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation.Nat Rev Immunol. 2007; 7:803–815. doi: 10.1038/nri2171CrossrefMedlineGoogle Scholar6. Elbadawi A, Elgendy IY, Sahai A, Bhandari R, McCarthy M, Gomes M, Bishop GJ, Bartholomew JR, Kapadia S, Cameron SJ. Incidence and outcomes of thrombotic events in symptomatic patients with COVID-19.Arterioscler Thromb Vasc Biol. 2021; 41:545–547. doi: 10.1161/ATVBAHA.120.315304LinkGoogle Scholar7. Iba T, Levy JH, Connors JM, Warkentin TE, Thachil J, Levi M. The unique characteristics of COVID-19 coagulopathy.Crit Care. 2020; 24:360. doi: 10.1186/s13054-020-03077-0CrossrefMedlineGoogle Scholar8. Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, et al. Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report.Chest. 2020; 158:1143–1163. doi: 10.1016/j.chest.2020.05.559CrossrefMedlineGoogle Scholar9. Iba T, Levy JH. Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis.J Thromb Haemost. 2018; 16:231–241. doi: 10.1111/jth.13911CrossrefMedlineGoogle Scholar10. Nicolai L, Leunig A, Brambs S, Kaiser R, Weinberger T, Weigand M, Muenchhoff M, Hellmuth JC, Ledderose S, Schulz H, et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy.Circulation. 2020; 142:1176–1189. doi: 10.1161/CIRCULATIONAHA.120.048488LinkGoogle Scholar11. Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, et al. A neutrophil activation signature predicts critical illness and mortality in COVID-19.Blood Adv. 2021; 5:1164–1177. doi: 10.1182/bloodadvances.2020003568CrossrefMedlineGoogle Scholar12. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate immunity.Nat Rev Immunol. 2013; 13:34–45. doi: 10.1038/nri3345CrossrefMedlineGoogle Scholar13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.Lancet. 2020; 395:497–506. doi: 10.1016/S0140-6736(20)30183-5CrossrefMedlineGoogle Scholar14. Tomashefski JF, Davies P, Boggis C, Greene R, Zapol WM, Reid LM. The pulmonary vascular lesions of the adult respiratory distress syndrome.Am J Pathol. 1983; 112:112–126.MedlineGoogle Scholar15. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019.J Clin Invest. 2020; 130:2620–2629. doi: 10.1172/JCI137244CrossrefMedlineGoogle Scholar16. Shi D, Yan R, Lv L, Jiang H, Lu Y, Sheng J, Xie J, Wu W, Xia J, Xu K, et al. The serum metabolome of COVID-19 patients is distinctive and predictive.Metabolism. 2021; 118:154739. doi: 10.1016/j.metabol.2021.154739CrossrefMedlineGoogle Scholar17. Gordon JS, Drazner MH. Biomarkers of cardiac stress and cytokine release syndrome in COVID-19 [published online March 5, 2021].Curr Heart Fail Rep. doi: 10.1007/s11897-021-00505-2CrossrefGoogle Scholar18. Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC.Int J Hematol. 2021; 113:24–33. doi: 10.1007/s12185-020-03053-yCrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Brill J, Mueck K, Cotton M, Tang B, Sandoval M, Kao L and Cotton B (2024) Impact of COVID status and blood group on complications in patients in hemorrhagic shock, Trauma Surgery & Acute Care Open, 10.1136/tsaco-2023-001250, 9:1, (e001250), Online publication date: 1-Mar-2024. Hwang Y, Piekos S, Sorensen T, Hood L and Hadlock J (2023) Adoption of a National Prophylactic Anticoagulation Guideline for Hospitalized Pregnant Women With COVID-19: Retrospective Cohort Study, JMIR Public Health and Surveillance, 10.2196/45586, 9, (e45586) Layug E, Apor A, Kuhn R and Tan M (2023) Mechanisms of pediatric ischemic strokes in COVID-19: a systematic review, Frontiers in Stroke, 10.3389/fstro.2023.1197714, 2 Su P, Wu Y, Xie F, Zheng Q, Chen L, Liu Z, Meng X, Zhou F and Zhang L (2023) A Review of Extracellular Vesicles in COVID‐19 Diagnosis, Treatment, and Prevention, Advanced Science, 10.1002/advs.202206095, 10:19, Online publication date: 1-Jul-2023. Klychnikova E, Zhuravel S, Ivanov I, Nikitina O, Tazina E, Bulanov A, Talyzin A, Popugaev K, Vladimirov V, Petrikov S and Bogdanova A (2023) Interrelation between the parameters of endogenous vascular regulation, oxidative stress and the markers of inflammatory response in COVID-19 patients while on extracorporeal membrane oxygenation, Transplantologiya. The Russian Journal of Transplantation, 10.23873/2074-0506-2023-15-1-10-22, 15:1, (10-22) Fessler S, Liu L, Chang Y, Yip T and Johnston C (2022) Palmitoylethanolamide Reduces Proinflammatory Markers in Unvaccinated Adults Recently Diagnosed with COVID-19: A Randomized Controlled Trial, The Journal of Nutrition, 10.1093/jn/nxac154, 152:10, (2218-2226), Online publication date: 1-Oct-2022. Wagner D and Heger L (2022) Thromboinflammation: From Atherosclerosis to COVID-19, Arteriosclerosis, Thrombosis, and Vascular Biology, 42:9, (1103-1112), Online publication date: 1-Sep-2022. Corriero A, Ribezzi M, Mele F, Angrisani C, Romaniello F, Daleno A, Loconsole D, Centrone F, Chironna M and Brienza N (2022) COVID-19 Variants in Critically Ill Patients: A Comparison of the Delta and Omicron Variant Profiles, Infectious Disease Reports, 10.3390/idr14030052, 14:3, (492-500) Charfeddine S, Ibnhadjamor H, Jdidi J, Torjmen S, Kraiem S, Bahloul A, Makni A, Kallel N, Moussa N, Boudaya M, Touil I, Ghrab A, Elghoul J, Meddeb Z, Thabet Y, Ben Salem K, Addad F, Bouslama K, Milouchi S, Hammami R, Abdessalem S and Abid L (2022) Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients With Long-COVID-19: Insights From TUN-EndCOV Study, Frontiers in Cardiovascular Medicine, 10.3389/fcvm.2022.866113, 9 Yim K, Borgoni S and Chahwan R (2022) Serum extracellular vesicles profiling is associated with COVID‐19 progression and immune responses, Journal of Extracellular Biology, 10.1002/jex2.37, 1:4, Online publication date: 1-Apr-2022. Nava-Santana C, Rodríguez-Armida M, Jiménez J, Vargas-Parra N, León D, Campos-Murguia A, Macías-Rodriguez R, Arteaga-Garrido A, Hernández-Villegas A, Dominguez-Cherit G, Rivero-Sigarroa E, Gamboa-Dominguez A, Gullias-Herrero A, Sifuentes-Osornio J, Uribe-Uribe N, Morales-Buenrostro L and Mukhopadhyay P (2022) Clinicopathologic characteristics of severe COVID-19 patients in Mexico City: A post-mortem analysis using a minimally invasive autopsy approach, PLOS ONE, 10.1371/journal.pone.0262783, 17:3, (e0262783) Sbirkov Y, Dzharov V, Todorova K, Hayrabedyan S and Sarafian V (2022) Endothelial inflammation and dysfunction in COVID-19, Vasa, 10.1024/0301-1526/a000991, 51:2, (62-70), Online publication date: 1-Mar-2022. Cicco S, Mozzini C, Carella R, De Fazio G, Vacca A, Cariddi C, Setti A, Pappagallo F, Solimando A and Ria R (2022) Cardiovascular Risk Score and Pulmonary Gas Exchange in COVID-19 Patients Show No Correlation Oxygen Transport to Tissue XLIII, 10.1007/978-3-031-14190-4_18, (105-109), . Cimolai N (2021) Untangling the Intricacies of Infection, Thrombosis, Vaccination, and Antiphospholipid Antibodies for COVID-19, SN Comprehensive Clinical Medicine, 10.1007/s42399-021-00992-3, 3:10, (2093-2108) Related articlesVascular Endothelial Damage in the Pathogenesis of Organ Injury in Severe COVID-19Annabelle Dupont, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021;41:1760-1773 May 2021Vol 41, Issue 5 Advertisement Article InformationMetrics © 2021 American Heart Association, Inc.https://doi.org/10.1161/ATVBAHA.121.316101PMID: 33792345 Originally publishedApril 1, 2021 KeywordsEditorialsacute lung injurycoronavirusCOVID-19disseminated intravascular coagulationendotheliumextracorporeal membrane oxygenationthrombosisPDF download Advertisement
Referência(s)